socalTECH

NOVEMBER 17, 2017

Amgen Ventures , the venture investment arm of Thousand Oaks-based Amgen , is one of the new investors in precision oncology and medicine startup Syapse.

Thousand Oaks 113

Thousand Oaks Funding Software Capital 113

socalTECH

MARCH 8, 2016

Thousand Oaks-based Amgen has made another investment this morning in immunology startup Tizona Therapeutics , via its venture capital arm, Amgen Ventures. Series A investors--including Amgen Ventures--also participated, with investments from MPM Capital, Astellas Venture Management and InterWest Partners.

Thousand Oaks 100

Thousand Oaks Funding Venture Capital Invest 100

socalTECH

OCTOBER 12, 2016

Thousand Oaks-based Akriveia Therapeutics , a biotechnology startup focused on immuno-oncology, announced this morning that it has raised $7.5M in a Series A investment. The investment came from F-Prime Capital Partners.

Thousand Oaks 100

Thousand Oaks Research Activity Invest 100

socalTECH

DECEMBER 17, 2013

Thousand Oaks-based biopharmaceuticals startup Atara Biotherapeutics announced this morning that it has raised $38.5M in a Series B funding round, for its efforts to develop treatments for patients with end-stage renal disease.

Thousand Oaks 180

Thousand Oaks Venture Capital Capital Funding 180

socalTECH

OCTOBER 9, 2015

Thousand Oaks-based Amgen has seen an exit out of its startup investment portfolio, and activities of its Amgen Ventures venture capital arm, at Berkeley-based Adheron Therapeutics this morning.

Thousand Oaks 100

Thousand Oaks Venture Capital Activity Capital 100

Xconomy

JULY 22, 2016

But there’s plenty more to dig through as well, from a shakeup at Zafgen to a few new high profile startups and a newly public gene therapy company. —Celgene (NASDAQ: CELG ), of Summit, NJ, inked its latest immuno-oncology deal, forming a wide-ranging alliance with Cambridge-based Jounce Therapeutics to develop a group of cancer drugs.

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

AUGUST 26, 2016

Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. —Pfizer wasn’t done after scooping up Medivation.

Pricing 40

Pricing Thousand Oaks Startup Research 40